

May 15, 2026

To,
National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra-Kurla Complex,
Bandra (East), Mumbai-400 051
Symbol: JLHL

To,
BSE Limited
P. J. Towers,
25th Floor, Dalal Street, Fort
Mumbai 400 001
Code: 543980

Subject: Investor Presentation for the quarter and year ended March 31, 2026

Reference: Unaudited Financial Results for the quarter ended March 31, 2026 and Audited Financial Results of the Company for the financial year ended March 31, 2026 (both Standalone and Consolidated)

Dear Sir/ Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time, please find the enclosed investor presentation for the Unaudited Financial Results for the quarter ended March 31, 2026 and Audited Financial Results of the Company for the financial year ended March 31, 2026 (both Standalone and Consolidated).

The same will be available on the website of the Company at www.jupiterhospital.com.

You are requested to kindly take the afore-mentioned on record and oblige.

Thanking you.

For JUPITER LIFE LINE HOSPITALS LIMITED

Suma Upparatti
Company Secretary & Compliance Officer

Encl.: As stated above.

IN THE PINK OF HEALTH.



Jupiter Life Line Hospitals Limited

**Results Presentation
Q4 & FY26**

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Jupiter Life Line Hospitals Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.



Dr. Ankit Thakker
JMD & CEO

Patient First

“FY26 has been a landmark year for us, marked by two significant milestones, acquisition of land at BKC for setting up a 400-bed hospital and operationalization of Dombivli hospital on 25th February 2026. The project was delivered on budget and before time, ahead of its scheduled launch date of Q1 FY27.


With this we will have four hospitals in MMR, two in Pune and one in Indore; further cementing our leadership position in Western India.

The ahead of schedule implementation of Dombivli hospital meant that the Q4 financials have been impacted by the drag of its opex losses and the depreciation on account of its capitalization.

I am pleased to report that the Thane, Pune and Indore hospital are performing on expected lines and the Pune South construction is progressing on schedule.”

FY26 Performance Highlights

Rs in Cr




- EBITDA impacted by initial ramp-up loss from Dombivli hospital
- Higher depreciation following commercialisation of Dombivli hospital
- Higher Finance costs owing to an increase in gross debt for ongoing capex
- PAT impacted due to new labour code changes


FY26 Operating Metrics

Operational Bed Capacity⁽¹⁾


Census Beds Non - Census Beds




Average Occupancy Rate⁽²⁾




IPD & OPD Volumes ('000)⁽³⁾



ARPOB⁽⁴⁾




ALOS (in Days)⁽⁵⁾



Payor Mix

Government Schemes Self Payors Insurance Companies



ARPOB rounded off to the nearest hundred *This is the Operational Income and EBITDA. Unbilled revenue and Doctors' provision are excluded

1) Operational beds includes census beds (bed available for mid-night occupancy such as intensive care units ("ICUs"), wards etc.) and non-census beds (all other bed available other than census beds, such as day-care beds, casualty beds etc.) (2) Average occupancy rate is calculated as census occupied bed days (i.e. midnight census of occupied census beds during the period) divided by available census bed days (i.e. census bed capacity multiplied by the applicable days in the relevant period) (3) Out-patient volume refers to the total number of Out-patient bills generated in a specific period. Inpatient volume refers to the total number of inpatient discharge in a specific period irrespective of admission date. (4) ARPOB is calculated as income from hospital services divided by census occupied bed days (i.e. midnight census of occupied census beds during the period) (5) ALOS is the average length of stay of patients in a specific period, calculated as census occupied bed days (i.e. midnight census of occupied census beds during the period) divided by inpatient volume.

Consolidated Profit & Loss Statement

Particulars (in Rs. Crs)	Q4FY26	Q4FY25	YoY	Q3FY26	QoQ	FY26	FY25	YoY
Revenue from Operations	371.7	323.1	15.1%	349.1	6.5%	1,435.6	1,245.4	15.3%
Other Income - Operational	16.1	13.9		16.3		64.2	57.0	
Total Income	387.8	337.0	15.1%	365.4	6.1%	1,499.8	1,302.4	15.2%
Cost of Goods Sold	73.7	67.0		69.0		287.3	255.5	
Gross Profit	314.1	270.0	16.3%	296.3	6.0%	1,212.5	1,046.9	15.8%
Gross Profit Margin	81.0%	80.1%		81.1%		80.8%	80.4%	
Employee Cost	67.7	56.6		63.6		256.3	225.2	
Professional Fees	91.6	79.3		86.7		364.0	305.3	
Other Expenses	65.6	54.6		62.6		248.9	216.3	
EBITDA	89.2	79.4	12.3%	83.4	7.0%	343.3	300.1	14.4%
EBITDA Margin	23.0%	23.6%		22.8%		22.9%	23.0%	
Depreciation	23.3	17.7		21.7		87.6	57.1	
EBIT	65.9	61.8	6.7%	61.7	6.9%	255.6	243.0	5.2%
EBIT Margin	17.0%	18.3%		16.9%		17.0%	18.7%	
Other Income - Finance	9.1	7.0		9.2		42.4	28.3	
Finance Cost	9.0	5.6		7.5		32.7	10.7	
Exceptional Item Gain / (Loss)*	1.5	0.0		-6.4		-4.9	0.0	
PBT	67.5	63.2	6.9%	56.9	18.6%	260.4	260.7	-0.1%
PBT Margin	17.4%	18.8%		15.6%		17.4%	20.0%	
Tax	17.3	18.1		14.4		66.2	66.9	
PAT	50.2	45.0	11.5%	42.5	18.2%	194.2	193.8	0.2%
PAT Margin	12.9%	13.4%		11.6%		12.9%	14.9%	
Basic EPS	7.66	6.89		6.49		29.59	29.47	

- EBITDA includes an operational loss of Rs 9.4 cr from Dombivli Hospital during the initial ramp-up phase
- Depreciation expense increased following the commercialisation of the Dombivli hospital
- Finance costs increased YoY owing to an increase in gross debt levels undertaken to fund ongoing capital expenditure.

*Statutory impact of New Labour codes

Consolidated Balance Sheet

Equity & Liabilities (in Rs. Crs)	Mar-26	Mar-25
Total Equity	1,544.1	1,356.4
Share Capital	65.6	65.6
Other Equity	1,478.5	1,290.7
Non-Controlling interest	0.0	0.1
Non-Current Liabilities	612.5	421.0
Financial Liabilities		
Borrowings	500.9	321.7
Lease liabilities	65.5	62.3
Provisions	16.5	11.2
Deferred Tax Liabilities	29.6	25.8
Current Liabilities	226.5	158.4
Financial Liabilities		
Borrowings	7.6	4.0
Lease liabilities	10.2	5.1
Trade Payables	95.5	69.1
Other financial Liabilities	70.9	51.3
Other Current Liabilities	29.7	23.4
Current tax liabilities (net)	3.4	3.5
Provisions	9.2	2.0
Total Equity & Liabilities	2,383.1	1,935.8

Assets (in Rs. Crs)	Mar-26	Mar-25
Non - Current Assets	1,698.2	1,243.2
Property Plant & Equipments	1,276.9	899.4
Right of use assets	99.1	74.1
CWIP	129.2	185.1
Other Intangible assets	7.9	4.6
Financial Assets		
Investments	0.1	0.1
Other Financial Assets	33.3	53.5
Deferred tax assets (net)	19.8	18.6
Other Non - Current Assets (Net)	131.9	7.8
Current Assets	684.9	692.6
Inventories	38.3	26.5
Financial Assets		
Investments	485.7	507.1
Trade receivables	75.5	43.2
Cash and cash equivalentents	54.8	92.5
Bank balances other than above	3.4	2.5
Other financial assets	6.5	2.7
Current tax assets (net)	6.5	6.2
Other Current Assets	14.2	11.9
Total Assets	2,383.1	1,935.8

Consolidated Cash Flow Statement

Particulars (in Rs. Crs)	FY26	FY25
Net Profit Before Tax	265.3	260.7
Adjustments for: Non -Cash Items / Other Investment or Financial Items	87.7	49.2
Operating profit before working capital changes	353.0	309.9
Changes in working capital	-21.4	21.0
Cash generated from Operations	331.6	330.9
Direct taxes paid (net of refund)	-63.9	-64.2
Net Cash from Operating Activities	267.7	266.7
Net Cash from Investing Activities	-441.9	-497.3
Net Cash from Financing Activities	136.5	296.7
Net Decrease in Cash and Cash equivalents	-37.7	66.1
Add: Cash & Cash equivalents at the beginning of the period	92.5	26.4
Cash & Cash equivalents at the end of the period	54.8	92.5

Next-Phase of Growth: Scaling Bed Capacity to 2,900

Hospitals	Bed Capacity	Capex/Bed (Excl. Land) (Rs in cr)	Remarks
-----------	--------------	--------------------------------------	---------

Recently Commissioned

Dombivli	500	1.0	Phase-wise commissioning underway, with ~200 beds operational and fit-outs completed for an additional 100 beds
----------	-----	-----	---

Greenfield

Pune II	500	1.2	Under construction
Mira - Bhayandar	300	1.3	Project currently at conceptualization and planning stage
BKC	400	1.5	Documentation & registration

Strong post IPO Expansion of 1,700 beds at an Average Cost/Bed of ~ Rs 1.5 Cr*

Strategic Priorities Behind Expansion


✓ Strategic land bank in high-demand micro markets

✓ Phased commissioning to optimize capital deployment

✓ Strong operating leverage from consolidated scale

*Including land cost

Bandra Kurla Complex (BKC) Hospital: Multispecialty quaternary care



The land parcel of across **1,07,923 sq. ft.**




Land cost* **Rs 354 cr** for a lease of **80 years**



Over 2/3 of Mumbai's population lives within **45 mins drive from BKC**. The proposed site is adjacent to the Bullet Train station and **15 mins from Mumbai airport**




Proposed bed capacity
400 Beds – Multispecialty quaternary care



Strong location with potential to become a hospital of national repute

BKC Hospital: in the heart of Mumbai's commercial district

Dombivli Hospital: Expansion in the Mumbai MMR Region



Construction Area: ~7,50,000 sq. ft.



Bed Capacity – Phase I

Civil Construction: 500 beds

Fitouts: 300 beds <> Operationalised: 200 beds



Operationalised on 25th Feb'26

OPD: Week of 2nd Feb'26



Phase I Capex ~ Rs 425 cr*



Construction completed in 25 months and project delivered ahead of scheduled Q1FY27 target date



Jupiter Life Line Hospitals Limited

CIN: L85100MH2002PLC137908

investor.relations@jupiterhospital.com



Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285

Mandar Chavan / Rahul Agarwal
mandar.chavan@sgapl.net / rahul.agarwal@sgapl.net
+91 96993 82195 / +91 98214 38864

Thank You